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1. Introduction
The Beckley Foundation Drug Policy Programme (BFDPP) is an initiative dedicated to providing a rigorous, independent 
review of the effectiveness of national and international drug policies. The aim of this programme of research and analysis 
is to assemble and disseminate material that supports the rational consideration of complex drug policy issues, and leads to 
a more effective management of the widespread use of psychoactive substances in the future. The BFDPP currently chairs 
the International Drug Policy Consortium (www.idpc.info), a global network of NGOs and professional networks who work 
together to promote objective debate around national and international drug policies, and provide advice and support to 
governments in the search for effective policies and programmes. 
Prisons play an important role in drug policy. They are used to 
punish people who break drug laws and they also hold a large 
number of people who have experience of drug use and drug 
problems. They therefore have an important part to play in attempts 
to reduce the harm caused by drugs. Imprisonment itself can be seen 
as one type of harm, as it causes problems for prisoners and their 
families and creates a large fi nancial burden for taxpayers. These 
harms and costs are diffi cult to calculate, but there is little evidence 
that large scale imprisonment of drug offenders has had the desired 
results in deterring drug use or reducing drug problems (Bewley-
Taylor, Trace, & Stevens, 2005). 
In this paper, we examine the international prevalence of drug 
users, drug use and related problems in prisons and we report on the 
problems that are related to the issue of drugs in prison. We go on 
to examine the international guidelines and effective responses that 
have been developed in this area in the last decade. The paper is a 
review of the literature, based on a search of bibliographic databases 
including Medline, PubMed, ISI as well as EMBASE and contacts 
with researchers and practitioners in the fi eld up to January 2007. 
We hope that this paper provides an accessible guide to policymakers 
and service designers who are considering the appropriate responses, 
or evaluating and refi ning existing responses, to drug use in prisons 
in their own country.
2. Drug users and drug use in prisons
Drug users form a large proportion of prison populations in most 
developed countries. It is estimated that approximately fi fty percent 
of prisoners in the European Union have had a history of drug 
use throughout their lives (Zurhold, Stöver, & Haasen, 2004), 
and over 80% in the USA (Mumola, 1999). Injecting drug users 
(IDUs) are vastly over-represented, often accounting for half of all 
prison inmates  (Dolan et al., 2007), but only 1-3% of the broader 
community (Aceijas et al., 2004). In the United Kingdom, 80% of 
surveyed prisoners reported having ever used any illicit drug (Boys 
et al., 2002). Of sentenced prisoners surveyed, 32% of men and 34% 
of women reported severe drug dependence on at least one illicit 
drug (Singleton, Farrell, & Meltzer, 2003).
It is also known that large proportions of the populations of 
problematic drug users have been in prison. In the United States, 
eighty percent of injecting drug users have experienced incarceration 
at least once in their lives (Dolan, 1999). A cross sectional survey 
across ten cities from nine European countries found that over half 
the sampled heroin and cocaine users had been in prison (March, 
Oviedo-Joekes, & Romero, 2006).
Many prisoners continue to use drugs while they are in prison, 
despite attempts to prevent the entry of illicit substances. 
Approximately 40% of surveyed prisoners reported using drugs 
inside prison (Singleton et al., 1997), although there are (some) 
suggestions that the use of cannabis, which is the most commonly 
used drug in British and many other prisons, has since fallen 
(Singleton et al., 2005). Heroin is also used in prison, including 
by injection. The percentage of heroin dependent prisoners who 
continue to inject in prisons ranges between 16% and 60% according 
to European studies reviewed by Stöver et al (2001). A more recent 
German study found that 75% of imprisoned injectors continued to 
inject in prison (Stark et al., 2006).
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behaviours. Prison authorities’ efforts to stop drugs coming in often 
leads to prisoners stopping their drug use, or using less frequently. 
However, there are other effects of placing offenders - some who 
have signifi cant histories of drug use and some who do not – in 
close confi nement with little constructive activity (Small et al. 2005; 
Swann & James, 1998).  
Some studies suggest that prisoners switch between drugs when 
they enter prison. The length of incarceration, programmes like 
mandatory drug testing (MDT) and psychosocial characteristics of 
prisoners have been reported to be the most important infl uences 
on such switching (Boys et al., 2002). In prisons that operate drug 
testing, some prisoners may switch to a drug with a short detection 
time (e.g. heroin) from one with a long detection time (e.g. cannabis) 
to minimise detection and punishment, although the numbers who 
reported doing this in an English survey of prisoners was small 
(Singleton et al, 2005). 
Prison may also be an environment in which people begin injecting 
heroin, as they meet experienced injectors in an environment where 
heroin is scarce (so encouraging injection as a more effi cient mode 
of administration) and where there is little else to do (Stöver, 2001). 
A cross-sectional survey conducted in all prisons in England and 
Wales indicated that a quarter of those who used heroin started 
doing so in prison (Boys et al, 2002). Six per cent of drug injectors 
from one Scottish prison and a quarter of the injectors from another 
started to inject while incarcerated (Gore, Bird, & Ross, 1995).  
There is a lack of information on drug use, IDU and HIV in prisons 
in developing and transition countries, which points to a lack of 
assessment and health care services. Unsystematic programme 
evaluation in prisons has also been highlighted (Dolan et al., 2004).
3. Prison as a risk environment
Drug users in prison represent three kinds of risk: Risk to public 
health; risk of reoffending; and risk to the security of the prison.
Drug misuse is seen as one of the three main health problems 
currently facing prison systems throughout Europe (MacDonald, 
2004) and HIV/AIDS is of particular concern. Prisoners are one of 
the four key populations which have a higher prevalence of HIV 
infection than the general population (Hellard & Aitken, 2004; 
UNAIDS, 2006a) and imprisonment has been listed as one of the 
“social structural” factors in creating risks of HIV transmission 
(Rhodes et al., 2005). The overlap in sexual and drug using networks 
between drug users who have been imprisoned and other social 
groups means that infectious diseases may spread from prisons to 
the whole society (Gyarmathy & Neaigus, 2005).
HIV prevalence is generally several times higher in prisons than 
in surrounding communities because of the considerable over-
representation of injecting drug users (IDUs) among prisoners 
(Gaughwin, Douglas, & Wodak, 1991). These prisoners may then go 
on to  share drug injecting equipment and have unprotected sex, both 
inside prison and back in the community (Estebanez et al., 2002; 
UNAIDS, 2006b). A qualitative examination of HIV risk related to 
injecting drugs inside British Columbia prison illuminates that ‘ the 
harms normally associated with drug addiction, and injection drug 
use are exacerbated in prison’ (Small et al., 2005: 831).
There have been at least fi ve outbreaks of HIV in prison documented. 
These outbreaks occurred in Scotland (29 cases, Taylor et al., 1995), 
Australia (4 cases, Dolan & Wodak, 1999), Lithuania (291 cases, 
Caplinskiene et al., 2003), Ukraine (unknown number, Gunchenko & 
Kozhan 1999) and Russia (400 cases, Nikolayev, 2001).
Worldwide evidence shows that injecting drugs and sharing 
equipment, sexual activities, tattooing and body piercing and 
physical assault are the main risk factors for HIV transmission in 
prison (Dolan & Wodak, 1999; Hellard & Aitken, 2004). Dolan et 
al (2004) have examined evidence of HIV transmission in prisons 
in developing and transitional countries. IDU was found to be main 
mode of transmission of HIV as well as viral hepatitis in Eastern 
Europe and Central Asia, East Asia and the Pacifi c regions (Dolan 
et al., 2004). Increased risk of HIV and viral hepatitis transmission 
in prison has been noted in the USA, Canada, Austria, Belgium, 
Ireland, Greece, Finland, France, Germany, Italy, Portugal, Russia, 
Australia, Iran, Thailand and Brazil (Beyrer et al., 2003; Burattini 
, 2000; Butler et al., 2003; Correctional Service Canada, 2003; 
Hellard, Hocking, & Crofts, 2004; Korte, Pykalainen, & Seppala, 
1998; Koulierakis et al, 1999; March, Oviedo-Joekes, & Romero, 
2007; Rotily et al., 2000; Rotily et al., 2001; Sarang et al., 2006; 
Small et al., 2005; Swartz, Lurigio, & Weiner, 2004; Wood et al., 
2005; Zamani et al., 2005).
Most countries lack adequate preventive measures and AIDS 
treatment in prisons (Lines et al., 2004). As a result, people in prison 
are placed at increased risk of HIV infection, and prisoners living 
with HIV/AIDS are placed at increased risk of health decline and 
premature death. 
As prisoners who are dependent on heroin often reduce their use 
while in prison, they lose their tolerance to opiates. This means 
that their body can no longer cope with the doses that they were 
taking before prison. So if they resume similar doses when they are 
released, they face a high risk of overdose and death. A Scottish 
study found that there was excess mortality in men who had been 
recently been released from prison, and that this could be attributed 
to loss of tolerance to heroin (Bird & Hutchinson, 2003). There 
is also the risk of prisoners dying while in prison, whether from 
suicide, loss of tolerance, or contaminated drugs.
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that there is a strong correlation between dependent drug use 
and offending (Brochu, Guyon, & Desjardins, 2001; Lurigio & 
Schwartz, 1999; Seddon, 2000). Many prisoners go back to lives 
of drugs and crime when they are released, and rates of reoffending 
amongst this group of prisoners are extremely high (Hough, 2002). 
This means that, if imprisonment can be used as an opportunity 
to address the prisoners’ dependence, there may be signifi cant 
benefi ts in reducing recidivism and the victimisation of the 
communities to which these prisoners return.
Often the most pressing reason for dealing with drugs is the 
immediate threat posed to the security of the prison. Drug use in 
prison is connected to bullying, assaults, corruption of prison staff 
and other threats to security, such as the presence of mobile phones 
(Penfold, Turnbull, & Webster, 2005). Phones may be smuggled into 
the prison to facilitate drug dealing, but can then also be used for 
planning escapes and other criminal activities.
4. International guidelines on drugs and 
HIV/AIDS Services in Prison
Assessment of serious drug involvement among prisoners shows the 
need for effective interventions (Leukefeld & Tims, 1992). Many 
developed countries have established some kind of standard for 
prisoners’ health care and harm reduction services (Dolan & Wodak, 
1999; Farell et al., 2005; Jürgens, 2006; Kothari, Marsden, & 
Strang, 2002; Leukefeld & Tims, 1992; Lines et al., 2004; Zurhold, 
Stöver, & Haasen, 2004).  Leukefeld and Tims (1992) highlight 
the signifi cance of drug-related services within prison: addressing 
institutional management, reduction in drug-seeking behaviours and 
engaging drug users in rehabilitation process during incarceration 
(as incarceration may be the only contact that these people have with 
treatment providers).
Increasingly, prisons have drawn the attention of international bodies 
that work in the fi eld of drugs and HIV. A variety of international 
instruments and declarations apply in this fi eld. On prison conditions, 
these include:
• Standard Minimum Rules for the Treatment of Prisoners 
(United Nations, 1955).
• Body of Principles for the Protection of All Persons under 
Any Form of Detention or Imprisonment (United Nations, 
1988).
• Basic Principles for the Treatment of Prisoners (United 
Nations, 1990).
• Recommendation No R (98)7 of the Committee of Ministers 
to Member States Concerning the Ethical and Organisational 
Aspects of Health Care in Prison (Council of Europe, 1998). 
On HIV, they include:
• The WHO Guidelines on HIV Infection and AIDS in Prisons 
(World Health Organization, 1993).
• International Guidelines on HIV/AIDS and Human Rights 
(United Nations, 1996). 
• Declaration of Commitment – United Nations General 
Assembly Special Session on HIV/AIDS (United Nations, 
2001).
There have also been a variety of specifi c guidelines on prisons, 
health, drugs and HIV from the Council of Europe (1988; 1993) and 
the World Health Organization (HIPP, 2001; Møller et al., 2007). 
These have tended to stress the principle of equivalence. This states 
that prisoners have the right to equivalent prevention and treatment 
services to those available outside prisons. It has been argued that, 
given the elevated risks of drug use and infectious diseases in prison, 
services should be particularly targeted at the prison environment 
(O’Brien & Stevens, 1997). 
The Dublin declaration on HIV/AIDS in Prisons called on all 
governments to pay urgent attention to the matter of HIV/AIDS in 
prisons and related hazards such as risky sexual behaviours and 
injecting drugs in prisons (Lines et al., 2004).  It recognised that not 
all drug users will cease using drugs just because they are in prison. 
Zero-tolerance policies lead them to fi nd unsafe ways to use drugs. 
There is therefore a role in prisons for programmes that reduce the 
harm associated with drug use.
Governments who deny prisoners’ access to the services that are 
available outside prison may face legal challenges for denying the 
human rights of prisoners. For example, the British government 
settled out of court in 2006 with a group of people who had been 
denied adequate detoxifi cation services in prison. It has also been 
sued for denying access to needle exchange in prison (in a case that 
has been referred to the European Court of Human Rights).
5. The provision of drug-related services 
in prison
Although numerous studies have examined various policies and 
interventions on drug use in general, few have focused on drug 
treatment and services in prisons (Jürgens, 2006). The provision 
of drug treatment in prison presents a considerable challenge and 
there is a lack of information that would assist public authorities in 
meeting this challenge. 
In many countries, limited resources are dedicated to prisons, and 
security often takes precedence over treatment and health needs. 
Balancing the security and safety needs of the prison authorities 
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the provision of effective drug treatment, prisons can have 
signifi cant impact in reducing the health-related and criminal 
impacts of dependent drug use, and can also reduce prison 
management problems as more prisoners take on treatment, rather 
than being involved in continued drug use and dealing.
Prisoners retain the right to adequate healthcare (Arnott, 2001; Lines 
et al., 2004).  Providing effective drug services in prison can also 
contribute to reductions in criminal recidivism (Dolan et al, 2005). 
However, the provision of such services can be diffi cult. Despite 
increases in the availability of drug services in prison, as seen in 
Europe in the 1990s (Stevens, 1998) treatment availability is often 
limited. Security concerns are raised if inmates are required to move 
between different areas of the prison for treatment. And there may be 
opposition to some treatment modalities among prison or government 
authorities. For example, methadone maintenance, which has become 
increasingly available in European prisons since the mid 1990s, is 
still provided on a patchy basis due to the desire to make prisoners 
abstain from drugs, the perception of methadone as a psychoactive 
drug that is unsuitable for therapy, a lack of understanding of 
dependence as a chronic disease and limited resources and 
expertise among prison administration and staff (Michels, Stöver, & 
Gerlach, 2007; Stöver, Hennebel, & Casselman, 2004). Methadone 
maintenance is also available in prison in Australia, Canada and 
Puerto Rico, but it remains limited in the USA (Dolan et al., 2005; 
Heimer et al., 2006; Rich et al., 2005; Sibbald, 2002).
Harm reduction strategies that are used outside prison are often 
regarded by prison administrations and staff as undermining the 
measures taken inside prison to reduce the supply of drugs (Stöver 
et al. 2001). There is often denial by prison authorities that the 
problem of drug use and injecting exists and there are limitations 
in the introduction of infection prevention services due to budget 
constraints or overcrowding (MacDonald 2004).  According to the 
Dublin declaration on HIV/AIDS in prisons in Europe and Central 
Asia (Lines et al., 2004: 3) ‘the failure to implement comprehensive 
programmes that are known to reduce the risk of HIV transmission 
in prisons and to promote the health of prisoners living with 
HIV/AIDS is often due to lack of political will or to policies that 
prioritize zero-tolerance to drug use over zero-tolerance to HIV/
AIDS.  For these and other reasons, there is limited availability of 
harm reduction services in the prisons of Central and Eastern Europe 
(MacDonald, 2005) and elsewhere. 
6. Evidence on effectiveness of drug 
treatment and harm reduction in prison
Evidence is available on detoxifi cation, maintenance prescribing, 
needle exchanges, drug-free units and therapeutic communities 
in prisons. It suggests that all drug services in prison should be 
based on an individualized assessment of the prisoner’s needs, 
leading to an effort to match these needs to appropriate services 
(Friedmann, Taxman, & Henderson, 2007). Treatments should also 
be provided in a systematic way in order to integrate the provision 
of the various evidence-based practices with each other, with prison 
security and the need for continuity with services and supervision 
in the community. For example, a qualitative English study recently 
found that tight controls on entry of drugs and a lack of adequate 
detoxifi cation had led to a high level of bullying, as some prisoners 
coerced other inmates who were receiving prescribed drugs to hand 
them over (Penfold, Turnbull, & Webster, 2005). This suggests that 
tight controls on entry should be combined with adequate provision 
of detoxifi cation or maintenance prescribing in order to minimise 
both illicit drug use and bullying within the prison. As another 
example, the effect of methadone maintenance in prison has been 
found to be enhanced when continuity of treatment is provided on 
release for those who receive opiate substitute drugs during their 
imprisonment (Dolan et al., 2005). 
The issue of aftercare is important. Some studies have suggested 
that aftercare is necessary to optimise the effects of in-prison drug 
treatment on reducing reoffending (Bullock, 2003), but there are 
methodological diffi culties with this research and the precise nature 
of effective aftercare is unknown (Pelissier, Jones, & Cadigan, 2007)
Detoxifi cation
Detoxifi cation is the management of withdrawal symptoms 
associated with the cessation of a drug of dependence. Clinical 
management of detoxifi cation in prison assists the reduction of drug 
use in prison and fulfi ls the principle of equivalence. It is the most 
common intervention provided to drug dependent offenders who are 
received into custody in the UK (Department of Health et al., 2006). 
Detoxifi cation can be managed in a number of ways, depending on 
the drug or drugs of dependence. Medical intervention may assist 
the detoxifi cation process, particularly in the case of opiate or severe 
alcohol dependence. Alternatively, detoxifi cation can be managed non-
medically, through the provision of psychological support and care. 
Methadone can be safely used in prisons to assist opiate withdrawal. 
Buprenorphine can also be offered but can be associated with inmate 
management concerns. Lofexidine is a viable, non-opiate alternative 
pharmacotherapy. Symptomatic treatments should also be available. 
In all cases, management of withdrawal in prison settings should be 
informed by assessment of
• The inmate’s severity of drug dependence (using a scale 
designed for this purpose).
• The inmate’s wishes.
• and, where possible, information provided by clinicians 
involved in the care and treatment of the inmate in the 
community (Ibid).
There is a danger that prisoners who have been detoxifi ed, and so 
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return to using their previous doses of illicit opiates. For this and 
other reasons, detoxifi cation services should lead on to other forms 
of support and should provide warnings of the dangers of overdose 
(Strang et al., 2003).
Recommendations: 
Due to the paucity of information regarding detoxifi cation in prison, 
the majority of recommendations are based on evidence gathered in 
community settings.
• All inmates should be assessed for substance dependence 
and risk of withdrawal
• Inmates experiencing opiate withdrawal should be 
offered a range of detoxifi cation methods, including 
pharmacotherapies and symptomatic treatment.
Drug-free wings and therapeutic communities 
Voluntary drug-free units or drug-free wings are a form of residential 
correctional treatment program with the primary objective of 
rehabilitating offenders with histories of illicit drug use. Inmates 
residing in drug-free wings are segregated from the general 
prison population and pledge to abstain from drug use, usually in 
return for increased privileges such as recreational facilities or 
improved accommodation. Inmates are regularly urine tested and 
punishments for a positive urinalysis include loss of privileges 
or expulsion from the program. Drug-free wings may assist 
inmates to reduce their drug use while in prison and to access drug 
treatment on release from prison. Further research, clarifying the 
elements of programmes conducted in drug-free wings and their 
long-term impacts on drug use and criminal recidivism, is required 
(Incorvaia & Kirby, 1997).  Drug free wings operate in several 
European countries and also for a small number of inmates in half 
of Australian prisons. The cost of a drug-free wing in Australia has 
been calculated as approximately $Aus 208 per prisoner per day. 
This was equivalent to the cost of keeping a prisoner in maximum 
security (Black, Dolan & Wodak 2004).
Therapeutic communities are intensive treatment programs for 
prisoners with a history of severe drug dependence, which can 
be provided to prisoners who have normally a substantial time of 
their sentence still to serve (in Europe normally 12-15 months). 
Therapeutic communities are drug free environment where intensive 
treatment, care and rehabilitation programs are offered on a 24-hour, 
residential basis.
A systematic review of available evidence on the effects of 
therapeutic communities found two high quality studies of TCs 
in prison in the USA (Smith, Gates, & Foxcroft, 2006). One 
of these studies found that an in-prison therapeutic community 
(plus aftercare) produced superior effects (in terms of reduced 
reimprisonment) than imprisonment without treatment (Wexler 
et al., 1999). The other found that an in-prison TC had superior 
effects for prisoners who had both mental health and substance use 
problems compared to in-prison mental health programmes (Sacks 
et al., 2004). These and other studies suggest that it is very important 
to provide aftercare when people are released from in-prison TCs. 
Without such aftercare, the benefi ts of the TC may be much smaller 
(Inciardi et al., 1997; Wexler et al., 1999). A potential limitation 
on the provision of therapeutic communities is that they are quite 
expensive to run. This was one of the reasons why the therapeutic 
community at Österåker Prison in Sweden was cut back, despite 
showing positive outcomes (Åke Farbring, 2000).
Whilst there is a conspicuous absence of research on the 
effectiveness of prison drug treatment in the UK and Europe there 
are examples of promising practice. These include the Österåker 
milieu therapy program and the 12-step treatment programme 
delivered in England by the Rehabilitation of Addicted Prisoners 
Trust (RAPt).  A small reconviction study reported that 25% of  
RAPt program graduates had been reconvicted of a standard list 
offence within one year of release from prison, compared to 38% 
of a comparison group of matched offenders (Liriano, 2002). This 
study again suggested that aftercare was important in sustaining the 
changes made in prison.
Other elements that have often been associated with successful drug 
treatment programmes in prison are that they are based on social 
learning theory, employ authority structures with clear rules and 
sanctions, anti criminal modelling and reinforcement of prosocial 
behaviour, train offenders in pragmatic personal and social problem 
solving, have programme staff that utilise community resources and 
encourage empathetic relationships between staff and participants.
Recommendations: 
• Existing drug-free wings and therapeutic communities  
should be evaluated.
• Specifi c program elements should be clearly defi ned and 
their impact on drug use and related criminal recidivism 
evaluated.
• Results of these evaluations should inform further decision-
making regarding the continuation or expansion of drug-free 
wings. 
• Therapeutic communities in prison seem to be effective, 
but are quite expensive, so alternative ways of delivering a 
more cost effective service are needed. This could include 
treatment in the community under a court order.
• Where treatment facilities are placed in prisons, adequate 
aftercare should also be provided.
Maintenance prescribing
Maintenance prescribing refers to the medium- to long-term 
provision of opioid agonists to heroin- or other opioid-dependent 
people for the purposes of suppressing opioid cravings and 
improving the health and social well-being of the patient (Cropsey, 
Villalobos, & St Clair, 2005; Hall, Ward, & Mattick, 1998). 
Methadone is the most commonly used drug for maintenance 
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The majority of research evidence on maintenance prescribing 
in the community focuses on methadone maintenance treatment 
(MMT). The goals of MMT include reducing heroin and other 
opioid use and reducing criminal behaviour by heroin users. MMT 
has recently been called “one of the most highly researched and 
evidence-based treatments for illicit drug dependence” (Trafton, 
Minkel, & Humphreys, 2006). MMT is associated with reductions in 
injecting drug use and reduced frequency of injecting, benefi ts that 
produce reductions in HIV, mortality and hepatitis C transmission 
and reincarceration (Dolan, Hall, & Wodak, 1996; Dolan & Wodak, 
1999).
An individual’s drug use is usually much less frequent in prison 
than in the community (Dolan et al., 1996). For this reason it 
is sometimes argued that maintenance prescribing in prison is 
unnecessary. However, it is the rarity of injecting in prison, and 
the risks associated with this practice, that heighten the need for 
maintenance treatment (Dolan, Hall, & Wodak, 1998). Moreover, 
there is evidence that people who are in MMT before imprisonment 
and are then incarcerated without MMT will tend to return to 
problematic drug use and injecting in prison (Bollini, 2001).
MMT in prison results in: reduced drug use, reduced transmission 
of blood borne viruses, reduced mortality and reduced recidivism 
and re-incarceration.  This is particularly true in the absence of other 
harm reduction measures in prison (Stöver et al., 2004). All prisoners 
with a history of heroin or other opioid dependence, including those 
already receiving MMT prior to imprisonment and those who wish 
to commence MMT in prison, should be able to access treatment. In 
areas where buprenorphine is available in the community, it should 
be available in prison. This enables continuity of care.
Recommendations: 
• Methadone maintenance treatment should be available 
to all prisoners with a history of heroin or other opioid 
dependence 
• Consideration should be given to offering at least one other 
form of maintenance treatment, for example, buprenorphine.
• Dosing levels must be adequate to suppress heroin cravings 
and withdrawal symptoms.
• Treatment should not be time-limited.
• Maintenance treatment programs in prison should be 
stringently evaluated
• Better links and continuity of care are needed between 
prisons and the community based services, in order to 
continue treatment when entering to prison or upon release
Needle exchange in prison
The evidence on prison needle exchange is limited by the small 
number of countries that have introduced it. But in most cases 
where it has been introduced, starting in Switzerland in 1992, it 
has been accompanied by evaluation. These evaluations have been 
summarised (Stöver & Nelles, 2003) and have tended to fi nd:
• Sharing of injecting equipment is dramatically reduced.
• No increase in injecting.
• No increase in drug use.
• No evidence of misuse of injecting equipment (e.g. to 
threaten or attack prison staff).
A study in two Berlin prisons found that rates of sharing of injecting 
equipment fell from 71% of imprisoned injectors to virtually none 
following the introduction of a needle exchange programme (Stark 
et al. 2006). There were no cases of HIV infection, but a few new 
Hepatitis C infections. This suggests that needle exchange in prison, 
as outside, may be more effective in preventing the transmission of 
HIV than HCV.
Recommendations:
• In countries where needle exchange is provided outside 
prison, consideration should also be given to providing it 
inside prison.
• The introduction of needle exchange programmes should 
be carefully prepared, including providing information and 
training for prison staff.
• The mode of delivery of needles and syringes (e.g. by hand, 
or by dispensing machine) should be chosen in accordance 
with the environment of the prison and the needs of its 
population.
• Other programmes for the prevention of HIV and viral 
Hepatitis, and other drug treatment programmes, should be 
provided alongside needle exchange programmes.
77. Conclusion
This brief review has demonstrated that drug use poses serious 
problems for prisons and that prisons are an important setting 
for the provision of drug and HIV services. Several international 
recommendations and guidelines have now pointed the way to 
increasing the coverage and quality of drug services in prison. The 
minimum standard to which prison drug services should aim is to 
provide an equivalent range and standard of drug services to that 
which is available outside the prison. Given the importance of prison 
as an environment for the development of drug problems and the 
transmission of HIV, consideration should also be given to providing 
drug services that are specifi c to the prison population.
A range of services that are effective outside prison have also 
been demonstrated to be valuable within prisons. These include 
detoxifi cation, maintenance prescribing, the provision of therapeutic 
communities and needle exchange. A variety of services will 
be necessary to meet the diverse needs of prisoners, who have 
different experiences and patterns of drug use. All these services 
will be most effective where they are integrated into a system 
that provides continuity of treatment as people enter and exit the 
prison environment. Drug use in prison is a serious problem which 
was, for a long time, neglected. Many countries are now taking up 
opportunities to provide effective services. There is still potential to 
improve prison drug services in order to reduce the damage done by 
drug use to the health and safety of prison staff, of prisoners and of 
the communities to which the prisoners will return.
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